Also known as: IBI362, LY3305677
Mazdutide is a synthetic once-weekly peptide that activates both the GLP-1 and glucagon receptors. It has been studied in multiple phase 1 to phase 3 human trials, mostly in China, plus a small body of animal and tissue work.
Mazdutide is a peptide agonist at both the GLP-1 receptor and the glucagon receptor [1][3]. In isolated human atrial tissue, its effect on contractile force was reduced by both a GLP-1 receptor blocker and a glucagon receptor blocker, consistent with action at both receptors in that tissue [6]. Hippocampal gene-expression and synaptic-marker changes seen in db/db mice are reported findings; whether mazdutide crosses the blood-brain barrier has not been established [5].
| Study | Model | Reported result | Source |
|---|---|---|---|
| GLORY-1 [1] | Human Adults, randomized, double-blind, placebo-controlled, China | Phase 3, 610 adults, 48 weeks. Primary endpoints: prespecified metabolic measures at week 32 (see publication). Published. | Peer-reviewed N Engl J Med 2025 |
| Phase 2 dose-ranging trial [2] | Human Adults, randomized, double-blind, placebo-controlled, China | Phase 2, 248 adults, 24 weeks, three dose levels vs placebo. Primary endpoint: percent change in body weight. Published. | Peer-reviewed Nat Commun 2023 |
| Phase 1b glycemic study [3] | Human Adults, randomized, placebo-controlled with open-label dulaglutide arm | Phase 1b, 43 adults, 12 weeks. Primary endpoints: safety and tolerability; HbA1c and glucose measures secondary. Published. | Peer-reviewed Nat Commun 2022 |
| DREAMS-1 and DREAMS-2 [4] | Human Adults, randomized; one placebo-controlled (320), one vs dulaglutide (731) | Two phase 3 trials, 24 and 28 weeks. Primary endpoint: change in HbA1c. Published back-to-back. | Peer-reviewed Nature 2025 |
| Hippocampus and behavior in db/db mice [5] | Mouse Leptin-receptor-deficient (db/db) male mice, 12 weeks, vs dulaglutide | Researchers reported body-weight, behavioral-test and hippocampal gene-expression (Bdnf, Psd95) differences vs comparator; see publication. | Peer-reviewed eBioMedicine 2025 |
| Atrial contractility [6] | Other animal Isolated human right atrial tissue; spontaneously beating mouse right atria | 10–100 nM increased atrial contractile force (n=9), reduced by GLP-1R and glucagon-receptor blockers; increased beating rate in mouse atria (n=8). | Conference abstract Clin Res Cardiol 2026 |
Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.
PureLab does not supply this compound. This page summarizes published research only.
